Navigation

2006/038 NICE issues final guidance on trastuzumab

NICE has today (Wednesday 23 August 2006) issued final guidance on Herceptin to the NHS, just three months after the drug was licensed by the regulatory authorities for use in early breast cancer. NICE recommends Herceptin for women with early stage HER2-positive breast cancer, except where there are concerns about the woman's cardiac function.

This page was last updated: 03 August 2007

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.